New developments in conditioning regimens before auto-SCT in multiple myeloma

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 911-915

  Moreau, P ^a   Attal, M ^b   Harousseau, J L ^c  

^a HÔTEL DIEU   (France)

^b CHU PURPAN   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

conditioning regimen; high dose melphalan; multiple myeloma

Indexed keywords

AMIFOSTINE; BORTEZOMIB; BUSULFAN; DEXAMETHASONE; DOXORUBICIN; HOLMIUM 4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONATE HO 166; INTERLEUKIN 6 ANTIBODY; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VINCRISTINE;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSIMETRY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HEALTH CARE QUALITY; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; MELPHALAN; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 79960197061     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.20     Document Type: Review

References (37)

1. Harousseau JL, Moreau P. Autologous hematopoietic stemcell transplantation for multiple myeloma. New Engl J Med 2009; 360: 2645-2654.
2. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114: 5436-5443.
3. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146.
4. Chanan-Kahn A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
5. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografter myeloma. J Clin Oncol 2010; 28: 2077-2084.
6. Mellqvist UH, Westin J, Gimsing P, Hjertner O, Lenhoff S, Laane E, et al. Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a nordic myeloma study group randomized phase III trial. Blood 2009; 114: 530a.
7. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker C, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289-3294.
8. Spencer A, Miles Prince H, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793.
9. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of total therapy improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115-3121.
10. Attal M, Cristini C, Marit G, Caillot D, Facon T, Hulin C, et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Edition) 2010; 28(15-suppl): abstract no. 8018a.
11. McCarthy PL, Owzar K, Anderson KC, Hofmeister C, Hassoun H, Hurd D, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Edition) 2010; 28(15-suppl): abstract no. 8017.
12. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763. (Pubitemid 24110915)
13. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872. (Pubitemid 18027425)
14. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
15. Björskstrand B. European group for blood and marrow transplantation registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-225.
16. Lahuerta JJ, Martinez-Lopez J, Grande C, Blade J, de la Serna J, Alegre A, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 2000; 109: 138-147. (Pubitemid 30340590)
17. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 trial. Blood 2002; 99: 731-735. (Pubitemid 34525530)
18. Philips GL, Meisenberg BR, Reece DE, Adams VR, Badros A, Brunner J, et al. Activity of single-agent melphalan 220 to mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004; 10: 473-483.
19. Moreau P, Milpied N, Mahé B, Juge-Morineau N, Rapp MJ, Bataille R, et al. Melphalan 220 mg/m2 followed by peripheral stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003-1006. (Pubitemid 29250844)
20. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000; 109: 661-664. (Pubitemid 30415199)
21. Moreau P, Hulin C, Garban F, Yacoub-Agha I, Benboubker L, Attal M, et al. Tandem autologous stem cell transplantation in high risk-de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397-403. (Pubitemid 43053569)
22. Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448-1454. (Pubitemid 350091380)
23. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, de la Rubia J, Rosinol L, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010; 95: 1913-1920.
24. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328. (Pubitemid 23304255)
25. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, et al. High-dose topotecan, melphalan and cyclophosphamide with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 2004; 45: 755-759. (Pubitemid 38256038)
26. Palumbo A, Bringhen S, Bruno B, Pia Falcone A, Liberati AM, Grasso M, et al. Melphalan 200 mg/m2 vs melphalan mg/m2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 2010; 115: 1873-1879.
27. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma. Blood 2003; 102: 2684-2691. (Pubitemid 37193613)
28. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson MP, Gastineau DA, et al. A phase I study of (153) Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118-125. (Pubitemid 40090086)
29. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, et al. A phase II study of (153) Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010; 85: 409-413.
30. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380. (Pubitemid 36302084)
31. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
32. Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, et al. Bortezomib ad high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood 2010; 115: 32-37.
33. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib-dexamethasone is superior to vincristine-doxorubicin- dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase 3 trial. J Clin Oncol 2010; 28: 4621-4629.
34. Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pretreated multiple myeloma. Bone Marrow Transplant 2011; 46: 764-765.
35. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010; 16: 5079-5086.
36. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, et al. Arsenic trioxide with ascorbic acid and highdose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008; 14: 1401-1407.
37. Giralt S. 200mg/m2 melphalan-the gold standard for multiple myeloma. Nat Reviews 2010; 7: 490-491.